Table 2. Summary of Analysis of HCC Incidence in Patients Receiving Tenofovir vs Entecavir in Overall and Subgroup Analyses.
| Variable | 3-y Follow-up | 5-y Follow-up | ||
|---|---|---|---|---|
| HR (95% CI)a | P value | HR (95% CI)a | P value | |
| Overall analysis | ||||
| Random-effects HR (shared frailty) | 0.87 (0.77-0.98) | .02 | 0.84 (0.76-0.94) | .001 |
| Stratified Cox HR | 0.87 (0.77-0.99) | .03 | 0.85 (0.76-0.94) | .002 |
| Patients with cirrhosis only | ||||
| Random-effects HR (shared frailty) | 0.46 (0.37-0.57) | <.001 | 0.55 (0.46-0.66) | <.001 |
| Stratified Cox HR | 0.63 (0.52-0.76) | <.001 | 0.67 (0.56-0.79) | <.001 |
| Clinical cohorts | ||||
| Random-effects HR (shared frailty) | 0.95 (0.80-1.12) | .53 | 0.92 (0.80-1.06) | .26 |
| Stratified Cox HR | 0.96 (0.81-1.14) | .62 | 0.92 (0.80-1.06) | .24 |
| Administrative database, proportionality violated | ||||
| Single-center studies | ||||
| Random-effects HR (shared frailty) | 0.85 (0.67-1.07) | .16 | 0.77 (0.64-0.94) | .01 |
| Stratified Cox HR | 0.87 (0.69-1.10) | .24 | 0.77 (0.63-0.94) | .01 |
| Multicenter studies | ||||
| Random-effects HR (shared frailty) | 0.89 (0.77-1.03) | .13 | 0.83 (0.73-0.94) | .003 |
| Stratified Cox HR | 0.89 (0.77-1.03) | .13 | 0.83 (0.73-0.94) | .004 |
| Treatment naive | ||||
| Random-effects HR (shared frailty) | 0.79 (0.68-0.93) | .004 | 0.80 (0.70-0.92) | .001 |
| Stratified Cox HR | 0.80 (0.68-0.93) | .004 | 0.80 (0.70-0.91) | .001 |
Abbreviations: HCC, hepatocellular carcinoma; HR, hazard ratio.
a
Calculated with entecavir as the reference group.